Inhibiting the HIV Integration Process: Past, Present, and the Future
暂无分享,去创建一个
[1] Cameron J. Schweitzer,et al. Proteomic analysis of early HIV-1 nucleoprotein complexes. , 2013, Journal of proteome research.
[2] D. Margolis,et al. Prospects for Treatment of Latent HIV , 2013, Clinical pharmacology and therapeutics.
[3] M. Humbert,et al. Phage display-directed discovery of LEDGF/p75 binding cyclic peptide inhibitors of HIV replication. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[4] G. Giannini,et al. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. , 2012, Future medicinal chemistry.
[5] Thomas S. Peat,et al. Small Molecule Inhibitors of the LEDGF Site of Human Immunodeficiency Virus Integrase Identified by Fragment Screening and Structure Based Design , 2012, PloS one.
[6] R. Chandra,et al. Inhibition of HIV-1 Integrase gene expression by 10-23 DNAzyme , 2012, Journal of Biosciences.
[7] Guixia Liu,et al. Identification of old drugs as potential inhibitors of HIV-1 integrase – human LEDGF/p75 interaction via molecular docking , 2012, Journal of Molecular Modeling.
[8] Stephen M. Shaw,et al. Small-Molecule Inhibitors of the LEDGF/p75 Binding Site of Integrase Block HIV Replication and Modulate Integrase Multimerization , 2012, Antimicrobial Agents and Chemotherapy.
[9] P. Cherepanov,et al. 3′-Processing and strand transfer catalysed by retroviral integrase in crystallo , 2012, The EMBO journal.
[10] Cristina Tintori,et al. Discovery of small molecule HIV-1 integrase dimerization inhibitors. , 2012, Bioorganic & medicinal chemistry letters.
[11] Xiaohong Liu,et al. New Class of HIV-1 Integrase (IN) Inhibitors with a Dual Mode of Action , 2012, The Journal of Biological Chemistry.
[12] I. Boros,et al. Elevated level of lysine 9‐acetylated histone H3 at the MDR1 promoter in multidrug‐resistant cells , 2012, Cancer science.
[13] A. Engelman,et al. Multimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors* , 2012, The Journal of Biological Chemistry.
[14] C. Katlama,et al. Dolutegravir for the treatment of HIV , 2012, Expert opinion on investigational drugs.
[15] F. Bushman,et al. LEDGF/p75-Independent HIV-1 Replication Demonstrates a Role for HRP-2 and Remains Sensitive to Inhibition by LEDGINs , 2012, PLoS pathogens.
[16] C. Tintori,et al. Development of an AlphaScreen-Based HIV-1 Integrase Dimerization Assay for Discovery of Novel Allosteric Inhibitors , 2012, Journal of biomolecular screening.
[17] Benjamin Young,et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. , 2012, The Lancet. Infectious diseases.
[18] M. Wainberg,et al. Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir , 2011, Journal of Virology.
[19] H. Benyamini,et al. A structural model of the HIV-1 Rev-integrase complex: the molecular basis of integrase regulation by Rev. , 2011, Biochemical and biophysical research communications.
[20] J. Newman,et al. Crystal Structures of Novel Allosteric Peptide Inhibitors of HIV Integrase Identify New Interactions at the LEDGF Binding Site , 2011, Chembiochem : a European journal of chemical biology.
[21] Yves Pommier,et al. Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572) , 2011, Molecular Pharmacology.
[22] Zeger Debyser,et al. 4-[1-(4-Fluorobenzyl)-4-hydroxy-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acid as a prototype to develop dual inhibitors of HIV-1 integration process. , 2011, Antiviral research.
[23] T. Masuda. Non-Enzymatic Functions of Retroviral Integrase: The Next Target for Novel Anti-HIV Drug Development , 2011, Front. Microbio..
[24] S. Piscitelli,et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults , 2011, AIDS.
[25] N. Neamati,et al. Design of HIV-1 integrase inhibitors targeting the catalytic domain as well as its interaction with LEDGF/p75: a scaffold hopping approach using salicylate and catechol groups. , 2011, Bioorganic & medicinal chemistry.
[26] T. Seki,et al. Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes , 2011, Antimicrobial Agents and Chemotherapy.
[27] K. Hertogs,et al. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor. , 2011, Antiviral research.
[28] K. Musier-Forsyth,et al. FRET analysis reveals distinct conformations of IN tetramers in the presence of viral DNA or LEDGF/p75 , 2011, Nucleic acids research.
[29] M. Wainberg,et al. The role of unintegrated DNA in HIV infection , 2011, Retrovirology.
[30] M. Giacca,et al. The TRIM family protein KAP1 inhibits HIV-1 integration. , 2011, Cell host & microbe.
[31] H. Roder,et al. Retroviral Integrases Promote Fraying of Viral DNA Ends* , 2011, The Journal of Biological Chemistry.
[32] Soo-Yon Rhee,et al. HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications , 2011, The Journal of infectious diseases.
[33] M. Kogan,et al. HIV-1 Accessory Protein Vpr: Relevance in the pathogenesis of HIV and potential for therapeutic intervention , 2011, Retrovirology.
[34] A. Prakash,et al. Dual inhibition: a novel promising pharmacological approach for different disease conditions , 2011, The Journal of pharmacy and pharmacology.
[35] Xiaohong Liu,et al. Dithiothreitol causes HIV-1 integrase dimer dissociation while agents interacting with the integrase dimer interface promote dimer formation. , 2011, Biochemistry.
[36] H. Benyamini,et al. Cyclic peptide inhibitors of HIV-1 integrase derived from the LEDGF/p75 protein. , 2010, Bioorganic & medicinal chemistry.
[37] Shigeru Miki,et al. In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor , 2010, Antimicrobial Agents and Chemotherapy.
[38] Zeger Debyser,et al. Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor. , 2010, Bioorganic & medicinal chemistry.
[39] Maxwell D. Cummings,et al. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance , 2010, Proceedings of the National Academy of Sciences.
[40] L. Stuyver,et al. Cross-Resistance Profile Determination of Two Second-Generation HIV-1 Integrase Inhibitors Using a Panel of Recombinant Viruses Derived from Raltegravir-Treated Clinical Isolates , 2010, Antimicrobial Agents and Chemotherapy.
[41] Y. Pommier,et al. Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies. , 2010, Bioorganic & medicinal chemistry.
[42] M. Wainberg,et al. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays , 2010, AIDS.
[43] A. Engelman,et al. Structure-based modeling of the functional HIV-1 intasome and its inhibition , 2010, Proceedings of the National Academy of Sciences.
[44] A. Friedler,et al. Specific eradication of HIV-1 from infected cultured cells , 2010, AIDS research and therapy.
[45] K. Uberla,et al. The human immunodeficiency virus type 1 Rev protein: ménage à trois during the early phase of the lentiviral replication cycle. , 2010, The Journal of general virology.
[46] A. Friedler,et al. Stimulation of the HIV-1 integrase enzymatic activity and cDNA integration by a peptide derived from the integrase protein. , 2010, Biopolymers.
[47] Luba Tchertanov,et al. Resistance to HIV-1 integrase inhibitors: A structural perspective. , 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[48] Hongtao Xu,et al. Identification of Novel Mutations Responsible for Resistance to MK-2048, a Second-Generation HIV-1 Integrase Inhibitor , 2010, Journal of Virology.
[49] Y. Pommier,et al. Peptide HIV-1 integrase inhibitors from HIV-1 gene products. , 2010, Journal of medicinal chemistry.
[50] A. Marchand,et al. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. , 2010, Nature chemical biology.
[51] A. Friedler,et al. A novel role for the viral Rev protein in promoting resistance to superinfection by human immunodeficiency virus type 1. , 2010, The Journal of general virology.
[52] S. Goff,et al. Interactions of Host Proteins with the Murine Leukemia Virus Integrase , 2010, Viruses.
[53] M. Parker,et al. Crystal structure of the HIV‐1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site , 2010, FEBS letters.
[54] Zvi Hayouka,et al. Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370. , 2010, Biochemical and biophysical research communications.
[55] Youcef Mehellou,et al. Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? , 2010, Journal of medicinal chemistry.
[56] A. Engelman,et al. Retroviral intasome assembly and inhibition of DNA strand transfer , 2010, Nature.
[57] B. Clotet,et al. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates , 2010, AIDS.
[58] A. Friedler,et al. Novel regulation of HIV-1 replication and pathogenicity: Rev inhibition of integration. , 2009, Protein engineering, design & selection : PEDS.
[59] A. Zolopa,et al. Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[60] E. Clercq. A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate , 2009 .
[61] C. Katlama,et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[62] P. Frange,et al. Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus , 2009, AIDS.
[63] M. Wainberg,et al. Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes , 2009, Retrovirology.
[64] J. Darlix,et al. Analysis of the Viral Elements Required in the Nuclear Import of HIV-1 DNA , 2009, Journal of Virology.
[65] S. Piscitelli,et al. Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers , 2009, Antimicrobial Agents and Chemotherapy.
[66] A. Curran,et al. Raltegravir, Etravirine, and Ritonavir-Boosted Darunavir: A Safe and Successful Rescue Regimen for Multidrug-Resistant HIV-1 Infection , 2009, Journal of acquired immune deficiency syndromes.
[67] M. Kvaratskhelia,et al. An Allosteric Mechanism for Inhibiting HIV-1 Integrase with a Small Molecule , 2009, Molecular Pharmacology.
[68] Kerim Babaoglu,et al. Affinities between the Binding Partners of the HIV-1 Integrase Dimer-Lens Epithelium-derived Growth Factor (IN Dimer-LEDGF) Complex , 2009, The Journal of Biological Chemistry.
[69] M. Giacca,et al. GCN5-dependent acetylation of HIV-1 integrase enhances viral integration , 2009, Retrovirology.
[70] M. Giacca,et al. GCN5-dependent acetylation of HIV-1 integrase enhances viral integration , 2009, Retrovirology.
[71] Z. Debyser,et al. Pharmacophore‐Based Discovery of Small‐Molecule Inhibitors of Protein–Protein Interactions between HIV‐1 Integrase and Cellular Cofactor LEDGF/p75 , 2009, ChemMedChem.
[72] D. Klein,et al. Virologic Outcomes of Changing Enfuvirtide to Raltegravir in HIV-1 Patients Well Controlled on an Enfuvirtide Based Regimen: 24-Week Results of the CHEER Study , 2009, Journal of acquired immune deficiency syndromes.
[73] W. Klaskala,et al. Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study , 2009, AIDS.
[74] S. Ikeda,et al. Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors. , 2009, Journal of medicinal chemistry.
[75] J. Rain,et al. Lens Epithelium-derived Growth Factor/p75 Interacts with the Transposase-derived DDE Domain of PogZ* , 2009, Journal of Biological Chemistry.
[76] C. Woodward,et al. Integrase Interacts with Nucleoporin NUP153 To Mediate the Nuclear Import of Human Immunodeficiency Virus Type 1 , 2009, Journal of Virology.
[77] L. Khachigian,et al. DNAzymes and their therapeutic possibilities , 2009, Internal medicine journal.
[78] D. Hazuda,et al. Scintillation proximity assays for mechanistic and pharmacological analyses of HIV-1 integration. , 2009, Methods.
[79] E. Garvey,et al. 1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position. , 2009, Bioorganic & medicinal chemistry letters.
[80] E. Garvey,et al. The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore. , 2009, Bioorganic & medicinal chemistry letters.
[81] Olga M. Klibanov,et al. Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. , 2009, Current opinion in investigational drugs.
[82] O. Wiest,et al. Inhibition of histone deacetylases: a pharmacological approach to the treatment of non-cancer disorders. , 2009, Current topics in medicinal chemistry.
[83] A. Friedler,et al. Peptides Derived from HIV-1 Integrase that Bind Rev Stimulate Viral Genome Integration , 2009, PloS one.
[84] D. Langley,et al. The terminal (catalytic) adenosine of the HIV LTR controls the kinetics of binding and dissociation of HIV integrase strand transfer inhibitors. , 2008, Biochemistry.
[85] R. Geleziunas,et al. Preclinical Evaluation of GS-9160, a Novel Inhibitor of Human Immunodeficiency Virus Type 1 Integrase , 2008, Antimicrobial Agents and Chemotherapy.
[86] Luba Tchertanov,et al. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation , 2008, Nucleic acids research.
[87] A. Saïb,et al. Integrase and integration: biochemical activities of HIV-1 integrase , 2008, Retrovirology.
[88] D. Richman,et al. 2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.
[89] F. Bailly,et al. Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain. , 2008, Journal of medicinal chemistry.
[90] V. Soriano,et al. Resistance to integrase inhibitors. , 2007, Journal of HIV therapy.
[91] K. Shokat,et al. Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases , 2008, Nature chemical biology.
[92] Hualiang Jiang,et al. D77, one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. , 2008, Biochemical and biophysical research communications.
[93] Hualiang Jiang,et al. Symmetrical 1-pyrrolidineacetamide showing anti-HIV activity through a new binding site on HIV-1 integrase , 2008, Acta Pharmacologica Sinica.
[94] Zeger Debyser,et al. Transportin-SR2 Imports HIV into the Nucleus , 2008, Current Biology.
[95] K. Hertogs,et al. Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors , 2008, Journal of Virology.
[96] D. Hazuda,et al. 10-Hydroxy-7,8-dihydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-1,9(2H,6H)-diones: potent, orally bioavailable HIV-1 integrase strand-transfer inhibitors with activity against integrase mutants. , 2008, Bioorganic & medicinal chemistry letters.
[97] D. Hazuda,et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. , 2008, The New England journal of medicine.
[98] Zeger Debyser,et al. Inhibitory profile of a LEDGF/p75 peptide against HIV‐1 integrase: Insight into integrase–DNA complex formation and catalysis , 2008, FEBS letters.
[99] Zhengqiang Wang,et al. Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: introducing a diketoacid functionality into delavirdine. , 2008, Bioorganic & medicinal chemistry.
[100] R. Dayam,et al. HIV-1 integrase inhibitors: 2005-2006 update. , 2008, Medicinal research reviews.
[101] A. Engelman,et al. The Lentiviral Integrase Binding Protein LEDGF/p75 and HIV-1 Replication , 2008, PLoS pathogens.
[102] Zhengqiang Wang,et al. Synthesis of pyrimidine and quinolone conjugates as a scaffold for dual inhibitors of HIV reverse transcriptase and integrase. , 2008, Bioorganic & medicinal chemistry letters.
[103] Luba Tchertanov,et al. Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro , 2008, Antimicrobial Agents and Chemotherapy.
[104] E. Garvey,et al. The Naphthyridinone GSK364735 Is a Novel, Potent Human Immunodeficiency Virus Type 1 Integrase Inhibitor and Antiretroviral , 2007, Antimicrobial Agents and Chemotherapy.
[105] M. Markowitz,et al. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1. , 2007, Drugs of today.
[106] M. Matsuoka,et al. Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137) , 2007, Journal of Virology.
[107] Laith Q Al-Mawsawi,et al. Blocking interactions between HIV-1 integrase and cellular cofactors: an emerging anti-retroviral strategy. , 2007, Trends in pharmacological sciences.
[108] C. Crumpacker,et al. Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study , 2007, Journal of acquired immune deficiency syndromes.
[109] R. Benarous,et al. Differential interaction of HIV-1 integrase and JPO2 with the C terminus of LEDGF/p75. , 2007, Journal of molecular biology.
[110] D. Hazuda,et al. Inhibition of Human Immunodeficiency Virus Type 1 Concerted Integration by Strand Transfer Inhibitors Which Recognize a Transient Structural Intermediate , 2007, Journal of Virology.
[111] N. Meanwell,et al. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. , 2007, Current opinion in investigational drugs.
[112] A. Engelman,et al. LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. , 2007, Genes & development.
[113] C. Salomon,et al. Rationally designed dual inhibitors of HIV reverse transcriptase and integrase. , 2007, Journal of medicinal chemistry.
[114] Alon Herschhorn,et al. Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr). , 2007, Journal of molecular biology.
[115] A. Friedler,et al. Interaction between HIV-1 Rev and Integrase Proteins , 2007, Journal of Biological Chemistry.
[116] Joseph Rosenbluh,et al. Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium , 2007, Proceedings of the National Academy of Sciences.
[117] Xiaojian Yao,et al. Interaction of Human Immunodeficiency Virus Type 1 Integrase with Cellular Nuclear Import Receptor Importin 7 and Its Impact on Viral Replication* , 2007, Journal of Biological Chemistry.
[118] C. Katlama,et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial , 2007, The Lancet.
[119] S. Goff,et al. Host factors exploited by retroviruses , 2007, Nature Reviews Microbiology.
[120] E. Novellino,et al. Cinnamoyl compounds as simple molecules that inhibit p300 histone acetyltransferase. , 2007, Journal of medicinal chemistry.
[121] Myriam Witvrouw,et al. Virus Evolution Reveals an Exclusive Role for LEDGF/p75 in Chromosomal Tethering of HIV , 2007, PLoS pathogens.
[122] R. Copeland,et al. Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.
[123] Youichi Suzuki,et al. The road to chromatin — nuclear entry of retroviruses , 2007, Nature Reviews Microbiology.
[124] Y. Pommier,et al. Probing HIV-1 Integrase Inhibitor Binding Sites with Position-Specific Integrase-DNA Cross-Linking Assays , 2007, Molecular Pharmacology.
[125] U. Koch,et al. From dihydroxypyrimidine carboxylic acids to carboxamide HIV-1 integrase inhibitors: SAR around the amide moiety. , 2007, Bioorganic & medicinal chemistry letters.
[126] M. Rowley,et al. 4,5-dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical species. , 2006, Journal of medicinal chemistry.
[127] Wulin Teo,et al. An Essential Role for LEDGF/p75 in HIV Integration , 2006, Science.
[128] N. Neamati,et al. Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome. , 2006, Bioorganic & medicinal chemistry letters.
[129] Jelle Hendrix,et al. Overexpression of the Lens Epithelium-Derived Growth Factor/p75 Integrase Binding Domain Inhibits Human Immunodeficiency Virus Replication , 2006, Journal of Virology.
[130] M. Horikoshi,et al. Simple histone acetylation plays a complex role in the regulation of gene expression. , 2006, Briefings in functional genomics & proteomics.
[131] M. Tsiang,et al. Design, synthesis, and biological evaluation of novel tricyclic HIV-1 integrase inhibitors by modification of its pyridine ring. , 2006, Bioorganic & medicinal chemistry letters.
[132] Myriam Witvrouw,et al. Discovery of a small-molecule HIV-1 integrase inhibitor-binding site. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[133] A. Engelman,et al. Transcriptional co-activator p75 binds and tethers the Myc-interacting protein JPO2 to chromatin , 2006, Journal of Cell Science.
[134] H. Mitsuya,et al. Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance , 2006, Cellular and Molecular Life Sciences.
[135] Wei Yang,et al. Stepwise analyses of metal ions in RNase H catalysis from substrate destabilization to product release , 2006, The EMBO journal.
[136] Y. Pommier,et al. Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action. , 2006, Journal of medicinal chemistry.
[137] C. Van den Haute,et al. Transient and Stable Knockdown of the Integrase Cofactor LEDGF/p75 Reveals Its Role in the Replication Cycle of Human Immunodeficiency Virus , 2006, Journal of Virology.
[138] Z. Debyser,et al. Cellular co-factors of HIV-1 integration. , 2006, Trends in biochemical sciences.
[139] J. Gervay-Hague,et al. Current Developments in HIV Chemotherapy , 2006, ChemMedChem.
[140] A. Engelman,et al. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[141] Sylvie Garneau-Tsodikova,et al. Protein posttranslational modifications: the chemistry of proteome diversifications. , 2005, Angewandte Chemie.
[142] M. Emerman,et al. The Cell Cycle Independence of HIV Infections Is Not Determined by Known Karyophilic Viral Elements , 2005, PLoS pathogens.
[143] M. Giacca,et al. Acetylation of HIV‐1 integrase by p300 regulates viral integration , 2005, The EMBO journal.
[144] Myriam Witvrouw,et al. Integrase Mutants Defective for Interaction with LEDGF/p75 Are Impaired in Chromosome Tethering and HIV-1 Replication* , 2005, Journal of Biological Chemistry.
[145] Alon Herschhorn,et al. Peptides Derived from the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 as Novel Inhibitors of the Viral Integrase* , 2005, Journal of Biological Chemistry.
[146] A. Engelman,et al. Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75 , 2005, Nature Structural &Molecular Biology.
[147] Y. Pommier,et al. Design, synthesis and biological evaluation of heteroaryl diketohexenoic and diketobutanoic acids as HIV-1 integrase inhibitors endowed with antiretroviral activity. , 2005, Farmaco.
[148] R. Di Santo,et al. 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. , 2005, Antiviral research.
[149] Marc C. Nicklaus,et al. Model of full-length HIV-1 integrase complexed with viral DNA as template for anti-HIV drug design , 2004, J. Comput. Aided Mol. Des..
[150] Tomozumi Imamichi,et al. Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors. , 2004, Current pharmaceutical design.
[151] Pamela A. Silver,et al. Identification of an Evolutionarily Conserved Domain in Human Lens Epithelium-derived Growth Factor/Transcriptional Co-activator p75 (LEDGF/p75) That Binds HIV-1 Integrase* , 2004, Journal of Biological Chemistry.
[152] Pamela A Silver,et al. Human cell proteins and human immunodeficiency virus DNA integration. , 2004, Frontiers in bioscience : a journal and virtual library.
[153] J. Kappes,et al. Evidence that Stable Retroviral Transduction and Cell Survival following DNA Integration Depend on Components of the Nonhomologous End Joining Repair Pathway , 2004, Journal of Virology.
[154] Mark Embrey,et al. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[155] D. Hazuda,et al. Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques , 2004, Science.
[156] S. A. Chow,et al. Requirement for Integrase during Reverse Transcription of Human Immunodeficiency Virus Type 1 and the Effect of Cysteine Mutations of Integrase on Its Interactions with Reverse Transcriptase , 2004, Journal of Virology.
[157] Robert Craigie,et al. Identification of an inhibitor-binding site to HIV-1 integrase with affinity acetylation and mass spectrometry. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[158] G. Kalpana,et al. Specificity of Interaction of INI1/hSNF5 with Retroviral Integrases and Its Functional Significance , 2004, Journal of Virology.
[159] J. Mouscadet,et al. The Human Polycomb Group EED Protein Interacts with the Integrase of Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.
[160] E. De Clercq,et al. Development of Resistance against Diketo Derivatives of Human Immunodeficiency Virus Type 1 by Progressive Accumulation of Integrase Mutations , 2003, Journal of Virology.
[161] R. Malathi,et al. Non-Watson Crick base pairs might stabilize RNA structural motifs in ribozymes — a comparative study of group-I intron structures , 2003, Journal of Biosciences.
[162] Marc C Nicklaus,et al. Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S). , 2003, Molecular pharmacology.
[163] F. Bailly,et al. Structure-activity relationships of HIV-1 integrase inhibitors--enzyme-ligand interactions. , 2003, Current medicinal chemistry.
[164] Ian F. Harrison,et al. Nuclear import of HIV‐1 intracellular reverse transcription complexes is mediated by importin 7 , 2003, The EMBO journal.
[165] B. Roques,et al. The (52-96) C-terminal domain of Vpr stimulates HIV-1 IN-mediated homologous strand transfer of mini-viral DNA. , 2003, Nucleic acids research.
[166] M. Shultz,et al. Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. , 2003, Bioorganic & medicinal chemistry letters.
[167] B. Roques,et al. NMR structure of the HIV-1 regulatory protein VPR. , 2003, Journal of molecular biology.
[168] D. Hazuda,et al. Inhibition of HIV-1 Ribonuclease H by a Novel Diketo Acid, 4-[5-(Benzoylamino)thien-2-yl]-2,4-dioxobutanoic Acid* , 2003, The Journal of Biological Chemistry.
[169] Linghang Zhuang,et al. Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. , 2003, Journal of medicinal chemistry.
[170] Zeger Debyser,et al. HIV-1 Integrase Forms Stable Tetramers and Associates with LEDGF/p75 Protein in Human Cells* , 2003, The Journal of Biological Chemistry.
[171] N. Sluis-Cremer,et al. Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. , 2002, European journal of biochemistry.
[172] Paul Shinn,et al. HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots , 2002, Cell.
[173] G. Bocharov,et al. Recombination: Multiply infected spleen cells in HIV patients , 2002, Nature.
[174] Jon Cohen. Confronting the Limits of Success , 2002, Science.
[175] Yun Tang,et al. Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. , 2002, Journal of medicinal chemistry.
[176] A. Hizi,et al. Inhibition of the integrases of human immunodeficiency viruses type 1 and type 2 by reverse transcriptases. , 2002, The Biochemical journal.
[177] Wei Yang,et al. Structure of a two‐domain fragment of HIV‐1 integrase: implications for domain organization in the intact protein , 2001, The EMBO journal.
[178] J. Mouscadet,et al. Peptide inhibitors of HIV-1 integrase dissociate the enzyme oligomers. , 2001, Biochemistry.
[179] G. Maga,et al. HIV‐1 reverse transcriptase and integrase enzymes physically interact and inhibit each other , 2001, FEBS letters.
[180] A. Banerjea,et al. Novel mono- and di-DNA-enzymes targeted to cleave TAT or TAT-REV RNA inhibit HIV-1 gene expression. , 2001, Antiviral Research.
[181] N. Jing,et al. Rational drug design of DNA oligonucleotides as HIV inhibitors. , 2001, Current drug targets. Infectious disorders.
[182] Robert Craigie,et al. HIV Integrase, a Brief Overview from Chemistry to Therapeutics* , 2001, The Journal of Biological Chemistry.
[183] O. Genilloud,et al. The complestatins as HIV-1 integrase inhibitors. Efficient isolation, structure elucidation, and inhibitory activities of isocomplestatin, chloropeptin I, new complestatins, A and B, and acid-hydrolysis products of chloropeptin I. , 2001, Journal of natural products.
[184] Frederic D. Bushman,et al. A quantitative assay for HIV DNA integration in vivo , 2001, Nature Medicine.
[185] J. Perona,et al. Making the most of metal ions , 2001, Nature Structural Biology.
[186] Tania A. Baker,et al. Comparative architecture of transposase and integrase complexes , 2001, Nature Structural Biology.
[187] G. Nabel,et al. Viral replication and the coactivators p300 and CBP. , 2000, Trends in microbiology.
[188] F. Bushman,et al. Repair of Gaps in Retroviral DNA Integration Intermediates , 2000, Journal of Virology.
[189] Amy S. Espeseth,et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[190] Y. Pommier,et al. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. , 2000, Molecular pharmacology.
[191] R M Stroud,et al. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[192] J A Grobler,et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. , 2000, Science.
[193] L. Chylack,et al. Lens epithelium-derived growth factor: effects on growth and survival of lens epithelial cells, keratinocytes, and fibroblasts. , 2000, Biochemical and biophysical research communications.
[194] P. Brown,et al. Stereospecificity of Reactions Catalyzed by HIV-1 Integrase* , 1999, The Journal of Biological Chemistry.
[195] G. Cohen,et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[196] T. Steitz. DNA Polymerases: Structural Diversity and Common Mechanisms* , 1999, The Journal of Biological Chemistry.
[197] Patrick L. Hindmarsh,et al. HMG Protein Family Members Stimulate Human Immunodeficiency Virus Type 1 and Avian Sarcoma Virus Concerted DNA Integration In Vitro , 1999, Journal of Virology.
[198] A. Gronenborn,et al. Solution structure of the His 12 → Cys mutant of the N‐terminal zinc binding domain of HIV‐1 integrase complexed to cadmium , 1998, Protein science : a publication of the Protein Society.
[199] E. Novellino,et al. Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: synthesis, biological evaluation, and molecular modeling. , 1998, Journal of medicinal chemistry.
[200] D. Davies,et al. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[201] F. Bushman,et al. Chromosome Structure and Human Immunodeficiency Virus Type 1 cDNA Integration: Centromeric Alphoid Repeats Are a Disfavored Target , 1998, Journal of Virology.
[202] F. Bushman,et al. Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition , 1997, Journal of virology.
[203] R. Siliciano,et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.
[204] F. Bushman,et al. HIV-1 cDNA Integration: Requirement of HMG I(Y) Protein for Function of Preintegration Complexes In Vitro , 1997, Cell.
[205] Y. Pommier,et al. Chemical Trapping of Ternary Complexes of Human Immunodeficiency Virus Type 1 Integrase, Divalent Metal, and DNA Substrates Containing an Abasic Site , 1996, The Journal of Biological Chemistry.
[206] S. Sarafianos,et al. Biochemical analysis of catalytically crucial aspartate mutants of human immunodeficiency virus type 1 reverse transcriptase. , 1996, Biochemistry.
[207] H. Buc,et al. The Metal Ion-induced Cooperative Binding of HIV-1 Integrase to DNA Exhibits a Marked Preference for Mn(II) Rather than Mg(II) (*) , 1996, The Journal of Biological Chemistry.
[208] Y. Pommier,et al. Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type 1 integrase. , 1995, Biochemistry.
[209] A M Gronenborn,et al. Solution structure of the DNA binding domain of HIV-1 integrase. , 1995, Biochemistry.
[210] A. Engelman,et al. Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication , 1995, Journal of virology.
[211] G. Crabtree,et al. Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. , 1994, Science.
[212] A. Engelman,et al. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. , 1994, Science.
[213] R R Breaker,et al. A DNA enzyme that cleaves RNA. , 1994, Chemistry & biology.
[214] M. Emerman,et al. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[215] J. Steitz,et al. A general two-metal-ion mechanism for catalytic RNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[216] M. Bukrinsky,et al. Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[217] Robert Craigie,et al. HIV-1 DNA integration: Mechanism of viral DNA cleavage and DNA strand transfer , 1991, Cell.
[218] R. Plasterk,et al. Human immunodeficiency virus integrase protein requires a subterminal position of its viral DNA recognition sequence for efficient cleavage , 1991, Journal of virology.
[219] F. Bushman,et al. A rapid in vitro assay for HIV DNA integration. , 1991, Nucleic acids research.
[220] W. Haseltine,et al. Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex , 1991, Journal of virology.
[221] T. Steitz,et al. Structural basis for the 3′‐5′ exonuclease activity of Escherichia coli DNA polymerase I: a two metal ion mechanism. , 1991, The EMBO journal.
[222] F. Bushman,et al. Retroviral DNA integration directed by HIV integration protein in vitro. , 1990, Science.
[223] P. Brown,et al. Human immunodeficiency virus integration in a cell-free system , 1990, Journal of virology.
[224] H. Masur,et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. , 1981, The New England journal of medicine.
[225] M. Gottlieb,et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. , 1981, The New England journal of medicine.
[226] C. Cunningham-Rundles,et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. , 1981, The New England journal of medicine.
[227] F. Muregi,et al. Novel rational drug design strategies with potential to revolutionize malaria chemotherapy. , 2011, Current medicinal chemistry.
[228] A. Friedler,et al. Integration of HIV-1 DNA Is Regulated by Interplay between Viral Rev and Cellular LEDGF/p75 Proteins , 2010, Molecular medicine.
[229] Xiaowu Chen,et al. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. , 2010, Antiviral research.
[230] A. Friedler,et al. Peptides derived from HIV‐1 Rev inhibit HIV‐1 integrase in a shiftide mechanism , 2008, Biopolymers.
[231] E. De Clercq. New approaches toward anti-HIV chemotherapy. , 2005, Journal of medicinal chemistry.
[232] E. Zubin,et al. HIV-1 integrase can process a 3'-end crosslinked substrate. , 2004, European journal of biochemistry.
[233] Y. Pommier,et al. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. , 2002, The Journal of biological chemistry.
[234] Y. Pommier,et al. In vitro human immunodeficiency virus type 1 integrase assays. , 2001, Methods in enzymology.